Hypha Labs net loss narrows 45.77% to $304,757 in Q3 FY26; operating loss shrinks 82.1% to $95,953
FUNI•Quarterly results
Hypha Labs posted a net loss of $304,757 in the quarter ended June 30, 2026, narrowing 45.77%.
Operating loss narrowed to $95,953 as total operating expenses fell 82.1% to $95,953.
Professional fees dropped 93% to $29,534, reflecting lower stock-based compensation, consulting services, and legal fees.
Product development outlook
Hypha aims to market its Hypha Micropearl bioreactor in the latter part of calendar 2026, pending design completion and testing.
Other expense and derivative loss
Other expense widened to $208,804, driven by higher interest expense; results also included a $54,295 derivative-liability fair-value loss.
